MG
CRSP icon

Michael Gelband’s CRISPR Therapeutics CRSP Stock Holding History

Michael Gelband’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
28,893
-106,236
-79% -$5.6M 0.01% 920
2026
Q1 		$6.43M Buy
+135,129
New +$7.13M 0.05% 360
2025
Q2 		– Sell
-91,303
Closed -$3.11M – 1547
2025
Q1 		$3.11M Buy
91,303
+43,463
+91% +$1.84M 0.03% 548
2024
Q4 		$1.88M Buy
+47,840
New +$2.26M 0.01% 735
2024
Q2 		– Sell
-16,682
Closed -$1.14M – 1600
2024
Q1 		$1.14M Buy
+16,682
New +$1.19M 0.01% 903
2023
Q4 		– Sell
-34,331
Closed -$1.56M – 1556
2023
Q3 		$1.56M Sell
34,331
-2,232
-6% -$115K 0.01% 770
2023
Q2 		$2.05M Sell
36,563
-16,257
-31% -$922K 0.02% 793
2023
Q1 		$2.39M Buy
52,820
+27,379
+108% +$1.33M 0.02% 807
2022
Q4 		$1.03M Buy
25,441
+8,221
+48% +$436K 0.02% 925
2022
Q3 		$1.13M Buy
+17,220
New +$1.25M 0.01% 1061
2022
Q1 		– Sell
-15,522
Closed -$1.18M – 2268
2021
Q4 		$1.18M Buy
15,522
+6,276
+68% +$548K 0.01% 986
2021
Q3 		$1.03M Buy
+9,246
New +$1.16M 0.01% 1010
2021
Q2 		– Sell
-2,514
Closed -$306K – 2422
2021
Q1 		$306K Sell
2,514
-3,328
-57% -$503K ﹤0.01% 1655
2020
Q4 		$894K Buy
+5,842
New +$691K 0.01% 910
2020
Q2 		– Sell
-6,242
Closed -$265K – 1806
2020
Q1 		$265K Buy
+6,242
New +$322K 0.01% 694

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's CRSP Position: Q2 2026 in Review

Michael Gelband reduced its CRISPR Therapeutics (CRSP) stake by 79% in Q2 2026, selling an estimated $5.6M and leaving 28,893 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #920.

Michael Gelband first reported a position in CRSP in Q1 2020 and has held it in 15 quarters since. The position peaked at $6.43M in Q1 2026. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Michael Gelband held 28,893 shares of CRISPR Therapeutics worth $1.58M as of Q2 2026.
  • Michael Gelband sold 106,236 CRISPR Therapeutics shares in Q2 2026, an estimated $5.6M.
  • CRISPR Therapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #920 holding.
  • Michael Gelband first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • Michael Gelband's CRISPR Therapeutics position peaked at $6.43M in Q1 2026.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.